Cargando…

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

BACKGROUND: The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases (aBMs) are not well established. This study investigates whether deferring BR until cerebral progression was superior to upf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monnet, Isabelle, Vergnenègre, Alain, Robinet, Gilles, Berard, Henri, Lamy, Regine, Falchero, Lionel, Vieillot, Sabine, Schott, Roland, Ricordel, Charles, Chouabe, Stephane, Thomas, Pascal, Gervais, Radj, Madroszyk, Anne, Abdiche, Samir, Chiappa, Anne Marie, Greillier, Laurent, Decroisette, Chantal, Auliac, Jean Bernard., Chouaïd, Christos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053829/ https://www.ncbi.nlm.nih.gov/pubmed/33948123 http://dx.doi.org/10.1177/17588359211006983

Ejemplares similares

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
por: Corre, Romain, et al.
Publicado: (2018)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
por: Vergnenegre, Alain, et al.
Publicado: (2019)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015)

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
por: Christos, Chouaid, et al.
Publicado: (2012)

Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
por: Renaud, Emmanuelle, et al.
Publicado: (2023)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
por: Vergnenègre, Alain, et al.
Publicado: (2019)

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
por: Arpin, Dominique, et al.
Publicado: (2020)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
por: Auliac, Jean-Bernard, et al.
Publicado: (2019)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
por: Nemunaitis, John, et al.
Publicado: (2015)

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
por: Vergnenègre, A, et al.
Publicado: (2013)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
por: Lesueur, Paul, et al.
Publicado: (2018)

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)
por: LeCaer, H, et al.
Publicado: (2011)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Carboplatin/pemetrexed: COVID-19 infection: 2 case reports
Publicado: (2021)

Carboplatin/pembrolizumab/pemetrexed: COVID-19 pneumonia: case report
Publicado: (2021)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Sinus arrhythmia caused by pemetrexed with carboplatin combination: A case report
por: Quan, Xianghua, et al.
Publicado: (2022)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
por: Chouaïd, Christos, et al.
Publicado: (2014)

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
por: Zhang, Guan-Zhong, et al.
Publicado: (2010)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette, Wolfgang, et al.
Publicado: (2017)

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Zinner, Ralph G., et al.
Publicado: (2015)

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
por: Zhu, Yixiang, et al.
Publicado: (2018)

Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin
por: Eichhoff, Gerhard
Publicado: (2020)

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
por: Shen, Xinglei, et al.
Publicado: (2011)

Acute cerebral arterial embolism following pemetrexed and carboplatin treatment in non-small-cell lung cancer: A case report
por: TAKEDA, MASAYUKI, et al.
Publicado: (2013)

Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non–Small Cell Lung Cancer
por: Brooks, Gabriel A., et al.
Publicado: (2018)

Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report
por: Sato, Takashi, et al.
Publicado: (2012)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer
por: Ozawa, Yuichi, et al.
Publicado: (2020)

Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
por: Pereira, José Rodrigues, et al.
Publicado: (2013)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
por: Hayashi, Toshinobu, et al.
Publicado: (2021)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_aivbf6jj6htpcs66d8ljkidevl